✨ Free AI Report
MannKind Corporation: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research MannKind Corporation
Company Research

MannKind Corporation: Business Overview, Financials & Competitive Analysis

MannKind Corporation scores 7/10 on the AskCyborg Cyborg Score (Strong). Innovative inhaled therapy platform with expanding cardiometabolic portfolio and significant FDA regulatory catalysts in 2026 positions MannKind for sustainable revenue growth. MannKind is well-positioned with a catalyst-rich 2026 featuring two upcoming FDA decisions and Phase 1b topline data for Nintedanib DPI. The company is poised for significant revenue and margin.

What is MannKind Corporation's industry? MannKind Corporation (mannkindcorp.com) operates in Biopharmaceuticals - Specialized in Inhaled Therapeutics and Cardiometabolic/Orphan Lung Disease Treatment. AskCyborg classifies MannKind Corporation under Biopharmaceuticals - Specialized in Inhaled Therapeutics and Cardiometabolic/Orphan Lung Disease Treatment in its company registry.

MannKind Corporation is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases. The company closed 2025 on...

7/ 10Strong

Cyborg Score thesis

Innovative inhaled therapy platform with expanding cardiometabolic portfolio and significant FDA regulatory catalysts in 2026...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Specialized in Inhaled Therapeutics and Cardiometabolic/Orphan Lung Disease Treatment
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest MannKind Corporation Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for MannKind Corporation

AskCyborg analysts argue the bull and bear cases for MannKind Corporation across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
MannKind Corporation OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

MannKind Corporation Overview

Pro stress-test →

MannKind Corporation is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases. The company closed 2025 on a high note with the acquisition of scPharmaceuticals and record fourth-quarter revenue surpassing $100 million. With two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation.

Strategic Profile

Pro stress-test →

MannKind is renowned for developing and commercializing inhaled therapeutic products, with its flagship product being Afrezza (insulin human) Inhalation Powder. The addition of Furoscix strengthens the company's cardiometabolic franchise, while Afrezza and United Therapeutics-related revenues continue to deliver sustained growth. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Competitive Landscape

Pro stress-test →

Limited awareness, slow market penetration, and rising competition from large pharma constrain growth despite strong trends favoring MannKind's inhaled therapies. Key competitors include Novo Nordisk and Eli Lilly in insulin/diabetes space, plus Janssen and Roche in pulmonary disease treatments. MannKind maintains strategic collaborations with United Therapeutics Corporation for Tyvaso DPI development and regulatory/commercial activities.

Industry Context

MannKind Corporation operates in Biopharmaceuticals - Specialized in Inhaled Therapeutics and Cardiometabolic/Orphan Lung Disease Treatment.

Key facts

Headquarters: Danbury, Connecticut and Westlake Village, California, United States · Revenue: $313.79M · Market cap: $1.71B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on MannKind Corporation.

  • Q4 2025 revenue exceeded $100 million, marking record performance following the scPharmaceuticals acquisition
  • Phase 2 trial (INFLO-2) initiated in idiopathic pulmonary fibrosis with first patient enrollment planned in Q2 2026, with FDA decision on Nintedanib DPI anticipated
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Fourth quarter 2025 financial results reported with record revenue exceeding $100 million
  • February 2026First patient enrolled in INHALE-1ST pediatric study evaluating Afrezza in newly-diagnosed type 1 diabetes youth
  • +2 moreTrack every material event for MannKind Corporation as it happens. Explore monitoring →
Get alerted when MannKind Corporation has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Tresiba/LevemirLong-acting injectable insulins competing in diabetes market→Mounjaro/HumalogAdvanced insulin therapies in diabetes management→UptraviPulmonary hypertension therapies→

Compare MannKind Corporation with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

MannKind Corporation operates in Biopharmaceuticals - Specialized in Inhaled Therapeutics and Cardiometabolic/Orphan Lung Disease Treatment. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Specialized in Inhaled Therapeutics and Cardiometabolic/Orphan Lung Disease Treatment research →
NEW · MCP server

Ask your AI assistant about MannKind Corporation

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare MannKind Corporation and its top competitor on Cyborg Score”
“What did MannKind Corporation do this quarter?”
“Is MannKind Corporation a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does MannKind Corporation do?+
MannKind Corporation is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases. The company closed 2025 on...
What is MannKind Corporation's Cyborg Score?+
MannKind Corporation has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are MannKind Corporation's main competitors?+
Named competitors include Tresiba/Levemir, Mounjaro/Humalog, Uptravi. The full competitive landscape is in the AskCyborg report.
How can I get the full MannKind Corporation research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the MannKind Corporation research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track MannKind Corporation over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.